CHRYSALIS-2 ✨ Amivantamabe + Lazertinibe em CPNPC com mutações atípicas de EGFR (≤2L) 👥 N=105 (16m) 🧬 G719X 56% | L861X 26% | S768I 23% 📊 ORR 52% | mDoR 14.1m | mPFS 11m ➡️ Atividade robusta em mutações atípicas de EGFR🚀.

🧬 ALK+ NSCLC Estudo multicêntrico retrospectivo (n=156) avaliou QT +/- continuação de alectinibe/lorlatinibe após progressão a TKIs. ↑ PFS (6,6 vs 3,5 m) ↑ OS (16,4 vs 11,4 m) ↓ progressão intracraniana (18,7% vs 34%) Sem novas toxicidades

#SITC25 Following positive final OS of HARMONi-A: #ivonescimab +chemo post osimertinib in EGFR+ #lungcancer presented by @LeXiuning ▶️ mOS 16 vs 14 mos ( HR 0.74 p=0.019) 👉🏽 first IO/VEGF therapy w survival advantage in EGFR+ 👉🏽is it due to the VEGF or the PD1 inhibition? 👉🏽

Review in JAMA on lung cancer in patients with no smoking history, who now make up about 20% of all new cases of lung cancer. The biology of these cancers is different, as is the treatment, but the gravity is the same. Read now at @JAMA_current. https://t.co/zQhQh7AJSs

#ESMO25 - OptiTROP-Lung 04 (Fase 3) 📌EGFRm mCPNPC (N=376), follow-up 18m 💊Sacituzumabe-tiromutecano pós-TKI x QT baseada em platina - PFS 8,3m x 4,3m - HR 0,49 - OS 18m 65% x 48% - HR 0,60 - EA G3 58% x 53%

🫁 GBOT na ESMO25 📚 ALINA Trial - atualização 4 ano 📊 DFS II–IIIA: HR 0,36 (95%CI 0,23–0,56); 4y: 74,5% vs 46,3% 📊 DFS IB–IIIA (ITT): HR 0.35; 4y: 75.5% vs 47.0% 🧠 CNS-DFS: HR 0,37; 90,4% vs 76,1% 💫 Tendência favorável em OS (98,4% vs 92,4%)

🫁 GBOT na ESMO25 📚 ELEVATE Trial (Fase III, N=270) 🎯CPNPC ALK + IB-IIIB ressecados 🔍Ensartinibe 225 mg/d vs placebo 2 anos (QT adj permitida) 📊DFS 24 m: 87% vs 57% (HR 0.20 p<0.0001) Sem novos sinais de toxicidade. 🚀 Potencial nova opção para ALK+ ressecado.

Great to see Prof. @perth_meso_dr present results of our international phase 3 #mesothelioma trial #DREAM3R today at #ESMO25 a really enjoyable academic trial collaboration between @TOGAANZ @PrECOGonc

🫁 #ESMO25 Plenária 📚 HARMONi-6 🔍Ivonesci + QT vs tisleli + QT 🎯 CPNPC escamoso, 1 L 📈 SLP: 11,1 vs 6,9 meses 💥 HR 0,60 (p<0,0001) 🔸 Independente de PD-L1 🔸 ORR: 76% vs 67% 🔸 Perfil de segurança manejável (hemorragia G≥3: 2%) 🚀Potencial mudança de prática clínica.

📢 #ESMO25 | Estudo PHAROS - fase 2. Encorafenibe + Binimetinibe mostrou benefício clínico duradouro em pacientes com CPNPC BRAF V600E. ▪️ Naive tto: ORR 75%, mPFS 30 m, mOS 47 m ▪️ Pré-tratados: ORR 49%, mPFS 9,3 m, mOS 22,7 m ▪️ Sem novos EAs ❗️opção interessante na 1L de tto

📍📍HARMONi-6: Ivos/ChT vs ChT/IO in 1L advanced sq-NSCLC ✅ mPFS 11.14 vs 6.9 mo HR 0.60 - ✅ Higher ORR and mDOR ✅ Low VEGF-rel AEs First phase 3 study to improve PFS outcomes compared to SoC- will this translate to an OS improvement? #ESMO25 #ESMOAmbassadors

HARMONi-6 🇨🇳 In 1L squamous NSCLC, ivonescimab + CTx ↑ PFS vs tislelizumab + CTx (11.1 vs 6.9 mo; HR 0.60) with consistent benefit across PD-L1 subgroups; OS immature; global trial pending. @OncoAlert @myESMO #ESMO25

We will face a shortage of oncologists as projected cancer cases rise and number of oncologists decreasing relative to demand. 25% of oncologists are 64y and older. Number of oncologists currently on pace to meet only 29% of demand in next 12 years. Gaps will widen.

🚨 Check our Top 10 #LungCancer abstracts for @myESMO 2025! We’ve hand-picked the must-see sessions with times, rooms & presenters 🔑 📅 Stay on track in Berlin and simply import these directly to your calendar by clicking this link: 👉 https://t.co/3zdKv9un4U Which lung

Preclinical data show that high-dose sucralose reshapes the microbiome, depletes arginine & impairs CD8+ T cells, reducing anti–PD1 efficacy. In 157 patients with melanoma and NSCLC, intake >0.16 mg/kg/d was linked to 2–3x worse survival. 1/2 https://t.co/zdPBI755ti @OncoAlert

How to write a scientific paper in fifteen steps. #ScientificPaper #PaperWriting @PLOSCompBiol https://t.co/GDMUxaZi5M

Metanálise dados reconstruídos avaliando IO+IO em CPCNP. N=2881 pts mCPNPC - Lancet Oncol. - bloqueio duplo (CTLA-4 + PD-1/PD-L1) melhora SG em subgrupos de pacientes com PD-L1 <1% e mutação de STK11 - ⁠Sem benefício na população geral ou diferença por histologia.

🧬 CD8+ e PD-1 como preditores de sobrevida no câncer: 🔬Análise prospectiva de 2023 biópsias tumorais: - CPCNP, CCR, mama, esôfago, cabeça/ pescoço, pâncreas, ovário - níveis ⬆️ CD8+ ou PD-1 intratumorais >> ⬇️ risco de morte (HR 0.62) - independente de TNM e do tto.

🚨 Estudo FRONT-BRAF - Lancet Oncol: CPCNP metastático BRAF V600E+, 1L com ICI ± QT mostrou benefício vs. iBRAF +MEK ✔ mOS 40 vs. 25m (HR 0.69) ✔ EAs semelhantes se iBRAF+MEK 1 ou 2L 🔎 Estudo multicêntrico, retrospectivo, reforçando necessidade de validação prospectiva.

The FRONT-BRAF study, investigating the optimal 1st-line treatment for patients w/ stage IV BRAF V600E-mut NSCLC, has just been published in @TheLancetOncol https://t.co/ijbh8g3iwk This is a global effort involving 17 major cancer centres across Italy, USA, France, & Brazil. 1/9